Floatz logo

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301)

Gastrointestinal Stromal Cancer

Washington University School of Medicineprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Gastrointestinal Stromal Cancer cohort.

Asset / SponsorPhaseRating
MIDAZOLAM
Blueprint Medicines Corporation
Phase 4BBB
Regorafenib
Institut Bergonié
Phase 4BBB
Esomeprazole
Erasmus Medical Center
Phase 4BB
CAFFEINE
Markus Joerger
Phase 4BB
Imatinib
M.D. Anderson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301) is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
ductal breast carcinoma in situDormant
CCC
Indicative ·
51 / 100
View asset →
invasive ductal breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →